Literature DB >> 26519200

Intestinal helminth coinfection is associated with mucosal lesions and poor response to therapy in American tegumentary leishmaniasis.

Rilza Beatriz G Azeredo-Coutinho1, Maria Inês Pimentel2, Graziela Maria Zanini3, Maria F Madeira2, Jamyra Iglesias Cataldo2, Armando O Schubach2, Leonardo Pereira Quintella4, Cintia Xavier de Mello2, Sergio C F Mendonça5.   

Abstract

The most severe clinical form of American tegumentary leishmaniasis (ATL) due to Leishmania braziliensis is mucosal leishmaniasis (ML), characterized by destructive lesions in the facial mucosa. We performed a retrospective cohort study of 109 ATL patients from Rio de Janeiro State, Brazil, where ATL is caused by L. braziliensis, to evaluate the influence of intestinal parasite coinfections in the clinical course of ATL. Parasitological stool examination (PSE) was performed with samples from all patients by the sedimentation, Kato-Katz and Baermann-Moraes methods. The diagnosis of ATL was made from lesion biopsies by direct observation of amastigotes in Giemsa-stained imprints, isolation of Leishmania promastigotes or histopathological examination. All patients were treated with meglumine antimoniate. Patients with positive PSE had a frequency of mucosal lesions significantly higher than those with negative PSE (p<0.005). The same was observed for infections with helminths in general (p<0.05), with nematodes (p<0.05) and with Ascaris lumbricoides (p<0.05), but not for protozoan infections. Patients with intestinal parasites had poor response to therapy (therapeutic failure or relapse) significantly more frequently than the patients with negative stool examination (p<0.005). A similar difference (p<0.005) was observed between patients with positive and negative results for intestinal helminths, but not for intestinal protozoa. Patients with positive PSE took significantly longer to heal than those with negative PSE (p<0.005). A similar difference was observed for intestinal helminth infections (p<0.005), but not for protozoan infections. Our results indicate a deleterious influence of intestinal helminth infections in the clinical course of ATL and evidence for the first time an association between ML and these coinfections, particularly with nematodes and A. lumbricoides.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Ascaris lumbricoides; Coinfection; Helminths; Leishmania (Viannia) braziliensis; Mucocutaneous leishmaniasis; Nematodes

Mesh:

Year:  2015        PMID: 26519200     DOI: 10.1016/j.actatropica.2015.10.015

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  9 in total

1.  Leishmania donovani molecules recognized by sera of filaria infected host facilitate filarial infection.

Authors:  Richa Verma; Vikas Kushwaha; Smriti Pandey; Jagadeshwar Reddy Thota; Preeti Vishwakarma; Naveen Parmar; Pawan Kumar Yadav; Prachi Tewari; Susanta Kar; Praveen Kumar Shukla; Puvvada Kalpana Murthy
Journal:  Parasitol Res       Date:  2018-06-26       Impact factor: 2.289

2.  Susceptibility of dendritic cells from individuals with schistosomiasis to infection by Leishmania braziliensis.

Authors:  Diego Mota Lopes; Tarcísio Vila Verde S de Almeida; Robson da Paixão de Souza; Luís Eduardo Viana Ribeiro; Brady Page; Jamille de Souza Fernandes; Edgar M Carvalho; Luciana Santos Cardoso
Journal:  Mol Immunol       Date:  2017-11-29       Impact factor: 4.407

3.  Disease severity in patients with visceral leishmaniasis is not altered by co-infection with intestinal parasites.

Authors:  Fitsumbrhan Tajebe; Mulusew Getahun; Emebet Adem; Asrat Hailu; Mulualem Lemma; Helina Fikre; John Raynes; Aschalew Tamiru; Zemenay Mulugeta; Ermias Diro; Frederic Toulza; Ziv Shkedy; Tadesse Ayele; Manuel Modolell; Markus Munder; Ingrid Müller; Yegnasew Takele; Pascale Kropf
Journal:  PLoS Negl Trop Dis       Date:  2017-07-21

4.  Socioenvironmental conditions and intestinal parasitic infections in Brazilian urban slums: a cross-sectional study.

Authors:  Caroline Ferraz Ignacio; Milena Enderson Chagas da Silva; Natasha Berendonk Handam; Maria de Fatima Leal Alencar; Adriana Sotero-Martins; Martha Macedo de Lima Barata; Antonio Henrique Almeida de Moraes
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-08-07       Impact factor: 1.846

Review 5.  Tegumentary leishmaniasis and coinfections other than HIV.

Authors:  Dalila Y Martínez; Kristien Verdonck; Paul M Kaye; Vanessa Adaui; Katja Polman; Alejandro Llanos-Cuentas; Jean-Claude Dujardin; Marleen Boelaert
Journal:  PLoS Negl Trop Dis       Date:  2018-03-01

6.  A Case-Control Study on the Association Between Intestinal Helminth Infections and Treatment Failure in Patients With Cutaneous Leishmaniasis.

Authors:  Dalila Y Martínez; Alejandro Llanos-Cuentas; Jean-Claude Dujardin; Katja Polman; Vanessa Adaui; Marleen Boelaert; Kristien Verdonck
Journal:  Open Forum Infect Dis       Date:  2020-05-12       Impact factor: 3.835

Review 7.  The Binomial Parasite-Host Immunity in the Healing Process and in Reactivation of Human Tegumentary Leishmaniasis.

Authors:  Fatima Conceição-Silva; Jessica Leite-Silva; Fernanda N Morgado
Journal:  Front Microbiol       Date:  2018-06-19       Impact factor: 5.640

8.  Meta-taxonomic analysis of prokaryotic and eukaryotic gut flora in stool samples from visceral leishmaniasis cases and endemic controls in Bihar State India.

Authors:  Rachael Lappan; Cajsa Classon; Shashi Kumar; Om Prakash Singh; Ricardo V de Almeida; Jaya Chakravarty; Poonam Kumari; Sangeeta Kansal; Shyam Sundar; Jenefer M Blackwell
Journal:  PLoS Negl Trop Dis       Date:  2019-09-06

9.  Previous History of American Tegumentary Leishmaniasis Alters Susceptibility and Immune Response Against Schistosoma mansoni Infection in Humans.

Authors:  Guilherme Silva Miranda; Samira Diniz Resende; Diogo Tavares Cardoso; Genil Mororó Araújo Camelo; Jeferson Kelvin Alves Oliveira Silva; Vanessa Normandio de Castro; Stefan Michael Geiger; Mariângela Carneiro; Deborah Negrão-Corrêa
Journal:  Front Immunol       Date:  2021-03-11       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.